Sign up to save your podcasts
Or
Share Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Optimizing First-Line Immunotherapy for Recurrent or Metastatic HNSCC
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-first-line-immunotherapy-for-recurrent-or-metastatic-hnscc/24359/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.50
Valid until: 03-05-2025
Claim your CME credit at https://reachmd.com/programs/cme/optimizing-first-line-immunotherapy-for-recurrent-or-metastatic-hnscc/24359/
In this series, Drs. Nabil Saba and Barbara Burtness review best practices for the use of immune checkpoint therapies in the treatment of head and neck squamous cell carcinoma. They discuss optimizing first-line immunotherapeutic regimens, using biomarkers to determine response to immunotherapy, managing immune-related adverse events, and overcoming barriers to equitable care.